Cetraxate raises levels of calcitonin gene-related peptide and substance P in human plasma.
Cetraxate hydrochloride (cetraxate), an anti-ulcer drug, produces a dose-related increase in mucosal blood flow. Recently, it was found that capsaicin-sensitive afferent nerves play an important role in gastric mucosal defence. Capsaicin stimulates afferent nerves and enhances the release of calcitonin gene-related peptide (CGRP) and substance P in the stomach. We studied the effect of cetraxate on human plasma CGRP and substance P in healthy subjects. Cetraxate (800 mg) or placebo were orally administered to five healthy males. Blood samples were taken before, and at 20, 40, 60, 90, 120, 180 and 240 min after administration, followed by the extracting procedure, and submitted to a highly sensitive enzyme immunoassay system for CGRP and substance P. Single administration of cetraxate caused significant increases in plasma CGRP concentration at 60-120 min compared with placebo. Cetraxate significantly increased plasma substance P levels at 40-90 min compared with placebo. In this study, we hypothesized that cetraxate might indirectly stimulate capsaicin-sensitive afferent nerves and increase mucosal blood flow, and that this may be a key mechanism underlying its gastroprotective action.
Katagiri
Fumihiko
F
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita 879-5593, Japan. FKATA@med.oita-u.ac.jp
Sato
Yuhki
Y
Itoh
Hiroki
H
Takeyama
Masaharu
M
D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide / Q000097:blood*; D006801:Humans; D008297:Male; D013373:Substance P / Q000097:blood*; D014148:Tranexamic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D013373:Substance P; C000665:cetraxate; D014148:Tranexamic Acid; D015740:Calcitonin Gene-Related Peptide